𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Intrathecal thyrotropin-releasing hormone therapy of amyotrophic lateral sclerosis

✍ Scribed by T. Stober; K. Schimrigk; S. Dietzsch; T. Thielen

Publisher
Springer
Year
1985
Tongue
English
Weight
207 KB
Volume
232
Category
Article
ISSN
0340-5354

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Current status of thyrotropin-releasing
Current status of thyrotropin-releasing hormone therapy in amyotrophic lateral sclerosis
πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 English βš– 277 KB

Amyotrophic lateral sclerosis (ALS) and its variants are feared progressive neurological diseases of which the etiology and pathogenesis are unknown and for which therapy is unavailable. In 1983, Engel and associates 1 11 reported that infusion of thyrotropin-releasing hormone (TRH) improved strengt

Gene therapy of amyotrophic lateral scle
Gene therapy of amyotrophic lateral sclerosis
✍ I. A. Zavalishin; N. P. Bochkov; Z. A. Suslina; M. N. Zakharova; V. Z. Tarantul; πŸ“‚ Article πŸ“… 2008 πŸ› Springer US 🌐 English βš– 144 KB
Therapeutic benefits of intrathecal prot
Therapeutic benefits of intrathecal protein therapy in a mouse model of amyotrophic lateral sclerosis
✍ Yasuyuki Ohta; Tatsushi Kamiya; Makiko Nagai; Tetsuya Nagata; Nobutoshi Morimoto πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 589 KB

## Abstract When fused with the protein transduction domain (PTD) derived from the human immunodeficiency virus TAT protein, proteins can cross the blood–brain barrier and cell membrane and transfer into several tissues, including the brain, making protein therapy feasible for various neurological